The expression and activity of MMPs are increased in residual tumor tissues after the termination of immunotherapy

Abstract

To investigate the invasive ability of the residual tumor cells after immunotherapy and explore the feasible approach suppressing the invasion, mice were inoculated with B16 cells, and then treated by gene therapy with p4-1BBL/psPD-1 or IFN-γ. The production and activities of MMP-9 and MMP-2 in residual tumor tissues were analyzed with gelatin zymography 1 day and 7 days after the termination of the immunotherapy. The production of MMP-9 and MMP-2 by B16 cells treated with IFN-γ was also analyzed. IFN-γ-treated B16 cells were inoculated to mice via subcutaneous injection. The invasion of tumor to muscular tissue was analyzed. Gene therapy with CH50 was used to suppress the invasive growth of tumor. The results showed that the expression and the activities of MMP-9 and MMP-2 were significantly increased 7 days after the end of immunotherapy. The response of tumor cells to ECM molecules was intensified after the removal of IFN-γ, resulting in significant increase of both the production and activities of MMP-9 and MMP-2, and the increased invasion of tumor. Gene therapy with CH50 effectively suppressed the invasive growth of tumor. It is concluded that the termination of immunotherapy may result in a higher metastatic potential of residual tumor cells. Suppressing tumor invasion by suitable treatment will improve the efficacy of immunotherapy.

Keywords

immunotherapy / tumor metastasis / interferon γ / matrix metalloproteinases

References

[1] XiaoH., HuangB., YuanY., et al.. PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res, 2007, 13: 1823-1830

[2] ChengY., DongQ., SunL. R., et al.. Correlation between expression of MMP-2, MMP-9, TIMP-2, TIMP-1 and metastasis of neuroblastoma. Chin J Oncol, 2005, 27(3): 164-166

[3] KerkeläE., Saarialho-KereU.. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol, 2003, 12: 109-125

[4] HeY. F., ZhangG. M., WangX. H., et al.. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol, 2004, 173: 4919-4928

[5] HeY. F., WangX. H., ZhangG. M., et al.. Sustained low-level expression of interferon-γ promotes tumor development: Potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother, 2005, 54: 891-897

[6] LiuY., HuangB., YuanY., et al.. Inhibition of hepatocarcinoma and tumor metastasis to liver by gene therapy with recombinant CBD-HepII polypeptide of fibronectin. Int J Cancer, 2007, 121: 184-192

[7] YoshidaH., KatayoseY., UnnoM., et al.. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity. Cancer Immunol Immunother, 2003, 52: 97-106

[8] YurkovetskyZ. R., ShurinG. V., BarryD. A., et al.. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. J Gene Med, 2006, 8: 129-137

[9] CheukA. T., MuftiG. J., GuinnB. A.. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther, 2004, 11: 215-226

[10] GollobJ. A., SciambiC. J., HuangZ., et al.. Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. Cancer Res, 2005, 65: 8869-8877

[11] KarmakarS., DharR., DasC.. Inhibition of cytotrophoblastic (JEG-3) cell invasion by interleukin 12 involves an interferon gamma-mediated pathway. J Biol Chem, 2004, 279: 55297-55307

[12] BelperioJ. A., KeaneM. P., ArenbergD. A., et al.. CXC chemokines in angiogenesis. J Leukocyte Biol, 2000, 68: 1-8

[13] DiasS., BoydR., BalkwillF.. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer, 1998, 78: 361-365

[14] MitolaS., StraslyM., PratoM., et al.. IL-12 regulates an endothelial cell-lymphocyte network: effect on metalloproteinase-9 production. J Immunol, 2003, 171: 3725-3733

[15] RüeggC., YilmazA., BielerG., et al.. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med, 1998, 4: 408-414

[16] StraslyM., CavalloF., GeunaM., et al.. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol, 2001, 166: 3890-3899

[17] YuZ. R., ZhangG. M., LiD., et al.. The inhibitory effect of recombinant polypeptide CH50 of fibronectin on invasion and angiogenesis of tumors. Chin J Oncol, 2006, 28(11): 815-819